Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Valeant Pharmaceuticals Intl (VRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form

PDUFA Date Is Aug. 27, 2018

VRX.TO : 28.60 (-5.64%)
VRX : 22.98 (-3.61%)
Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Valeant Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / January 11, 2018 / All three major indexes dropped Wednesday on news that China is considering halting the purchases of U.S. sovereign debt, with the S&P 500 and Nasdaq logging...

SRPT : 60.15 (-2.23%)
VRX : 22.98 (-3.61%)
Valeant Provides Company Update At The 36th Annual J.P. Morgan Healthcare Conference

Seven Key Products Are Projected to Generate $1 Billion in Sales in 5 Years

VRX.TO : 28.60 (-5.64%)
JPM : 112.27 (-0.36%)
VRX : 22.98 (-3.61%)
Valeant Provides Company Update At The 36th Annual J.P. Morgan Healthcare Conference

Seven Key Products Are Projected to Generate $1 Billion in Sales in 5 Years

VRX.TO : 28.60 (-5.64%)
VRX : 22.98 (-3.61%)
Today's Research Reports on Stocks to Watch: Sarepta Therapeutics and Valeant Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / January 8, 2018 / Shares of Sarepta Therapeutics fell over 5% this past Friday. It was revealed that the company's former CEO is now heading a new local start up called Stoke...

SRPT : 60.15 (-2.23%)
VRX : 22.98 (-3.61%)
Bausch + Lomb Receives CE Mark From The European Commission For The Stellaris Elite(TM) Vision Enhancement System, Including The Vitesse(TM) Vitrectomy System

Next-Generation Ophthalmic Surgical Platform Now Available Across Greater Europe

VRX.TO : 28.60 (-5.64%)
VRX : 22.98 (-3.61%)
Valeant Pays Down $300 Million Of Senior Secured Term Loans

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced it has paid down an additional $300 million of its senior secured term loans, using cash...

VRX.TO : 28.60 (-5.64%)
VRX : 22.98 (-3.61%)
Valeant To Present At The 36th Annual J.P. Morgan Healthcare Conference

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to present at the 36th Annual J.P....

VRX.TO : 28.60 (-5.64%)
JPM : 112.27 (-0.36%)
VRX : 22.98 (-3.61%)
Valeant (VRX) to Settle Allergan Litigation for $290 Million

Valeant (VRX) and Pershing Square decided to resolve the claims of the long standing Allergan lawsuit for $290 million. Valeant will now pay 33% of the costs, down from the previous agreement of 60%.

SCMP : 18.05 (unch)
AGN : 178.66 (+1.48%)
EXEL : 29.65 (-2.40%)
VRX : 22.98 (-3.61%)
Valeant Announces Preliminary Resolution Of Allergan Shareholder Securities Litigation

Valeant Will Pay $96.25 Million to Resolve the Litigation

VRX.TO : 28.60 (-5.64%)
AGN : 178.66 (+1.48%)
VRX : 22.98 (-3.61%)
Valeant Announces Preliminary Resolution Of Allergan Shareholder Securities Litigation

Valeant Will Pay $96.25 Million to Resolve the Litigation

VRX.TO : 28.60 (-5.64%)
VRX : 22.98 (-3.61%)
Mallinckrodt to Buy Sucampo for $1.2B to Diversify Portfolio

Mallinckrodt (MNK) is all set to acquire Sucampo Pharmaceuticals to diversify its portfolio and counter the decline in sales of its largest drug, Acthar.

SCMP : 18.05 (unch)
PX : 162.10 (-1.25%)
MNK : 23.13 (-1.57%)
VRX : 22.98 (-3.61%)
Bausch + Lomb Receives FDA Approval of LUMIFY(TM) - The Only Over-The-Counter Eye Drop With Low-Dose Brimonidine For The Treatment Of Eye Redness

Clinical Studies Showed 95% Symptom Improvement At One Minute, And Reduced Redness For Up To Eight Hours

VRX.TO : 28.60 (-5.64%)
VRX : 22.98 (-3.61%)
Jazz Submits NDA to FDA for JZP-110 to Cure Sleep Disorder

Jazz submits a new drug application to the FDA for JZP-110 (solriamfetol) for treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea.

CORT : 21.31 (+3.20%)
JAZZ : 149.80 (-0.26%)
NVS : 86.73 (+0.09%)
VRX : 22.98 (-3.61%)
VRX Investor Alert: Kyros Law is Investigating Legal Claims on Behalf of Valeant Pharmaceuticals Intl (NYSE: VRX) Investors

Kyros Law Offices is alerting investors of Valeant Pharmaceuticals Intl (NYSE: VRX) that it is investigating legal claims against the company for possible securities fraud violations committed by Valeant...

VRX : 22.98 (-3.61%)
Valeant Completes Sale Of Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals

LAVAL, Quebec , Dec. 20, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced that its affiliate has completed the...

VRX.TO : 28.60 (-5.64%)
VRX : 22.98 (-3.61%)
Are Options Traders Betting on a Big Move in Valeant Pharmaceuticals (VRX) Stock?

Surging implied volatility makes Valeant Pharmaceuticals (VRX) stock lucrative to the option traders.

VRX : 22.98 (-3.61%)
Aerie (AERI) Gets Early FDA Approval for Lead Drug Rhopressa

Aerie (AERI) got a significant boost with the FDA approving its lead drug Rhopressa for the lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension,...

AERI : 57.10 (-2.56%)
AGN : 178.66 (+1.48%)
NVS : 86.73 (+0.09%)
VRX : 22.98 (-3.61%)
Bausch + Lomb Begins Distribution Of VYZULTA(TM) (latanoprostene bunod ophthalmic solution), 0.024% To U.S. Wholesalers

Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) ("Valeant") wholly owned subsidiary, Bausch + Lomb, a leading global eye health company, today announced that it has begun distributing...

VRX.TO : 28.60 (-5.64%)
VRX : 22.98 (-3.61%)
Bausch + Lomb Begins Distribution Of VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024% To U.S. Wholesalers

LAVAL, Quebec , Dec. 18, 2017 /PRNewswire/ --  Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) ("Valeant") wholly owned subsidiary, Bausch + Lomb, a leading global eye health...

VRX.TO : 28.60 (-5.64%)
VRX : 22.98 (-3.61%)

Van Meerten Stock Picks

My 5 Favorite Mid Cap Stocks
This morning I wanted to find 5 Mid Cap stocks that had great returns over the past year and still seem to have some juice left.
KBH -1.63 , IPGP +2.02 , FSLR -2.19 , NVR -17.23 , SGMS +0.25
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 +0.39%) are up +0.41% at a fresh record nearest-futures high as growth optimism fuels gains in global equity markets. Gains in technology stocks are leading the overall market higher as... Read More

Chart of the Day

Chart of the Day

Audentes Therapeutcs (BOLD) is rhe Barchart Chart of the Day.  The biomedical company has a Trend Spotter buy signal, a Weighted Alpha of 174.58+ and gained 111.74% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures bounced back from Friday’s bearish USDA reports to close Tuesday with gains of 2 cents in most nearby contracts. The weekly Export Inspections report indicated just 584,389 MT of corn was shipped during the week of Jan 11. That is ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.